Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that various commonly prescribed medications for chronic conditions may impact male fertility by affecting hormone secretion, sperm production, ejaculation, erectile function, and libido, although conclusive evidence is limited to specific drug groups.

This study found that gender-affirming hormone therapy in transgender men increased acne and male pattern hair loss, while in transgender women, it led to melasma and female pattern hair loss.

This study found that adequate vitamin D status is necessary for metformin to effectively reduce prolactin levels in men with iatrogenic hyperprolactinemia, while improvements in glycemic control were observed across all vitamin D groups.

This paper discusses four rare causes of hyperandrogenism in women, emphasizing the importance of detailed biochemical testing and invasive diagnostic tools when imaging fails to identify ovarian tumors.

This study found that metformin's effect on reducing prolactin levels is less pronounced in women with PCOS compared to control subjects, likely due to higher endogenous testosterone levels, despite improvements in insulin sensitivity in both groups after six months of treatment.

This case report describes a 29-year-old female with resistant polycystic ovary syndrome who experienced symptom relief following a unilateral oophorectomy.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This review examines the pathogenesis of androgen excess and dyslipidemia in PCOS and the potential role of statins as a treatment but provides no new clinical results.

This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.

This review discusses hormonal treatment strategies for both binary and non-binary transgender people, highlighting the need for personalized approaches and the importance of future research on long-term outcomes.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

A new method can almost perfectly distinguish adenomyosis from similar conditions using blood tests.

In this pilot study, finasteride increased testosterone/dihydrotestosterone and progesterone/dihydroprogesterone ratios in normal ovulatory women but did not alter ovulation or gonadotropin secretion.

This review discusses various substances that can impact male fertility and stresses that products should be confirmed 'sperm-safe' through rigorous testing, not assumptions; it reports no new study results.

This study reported the development of fluorescent markers using wide band gap metal oxides with rare earth ions for early tumor detection and treatment. Testing in animals showed high efficiency and selectivity, with potential applications in contrast-enhanced MRI, targeted drug delivery, and photodynamic cancer therapy.

In this study, a child's diagnosis of Silver-Russell syndrome was confirmed through phenotype data, genetic testing, and the exclusion of other developmental conditions, revealing a need for a multidisciplinary care approach.

This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This article discusses the symptoms, diagnosis, and treatments of polycystic ovarian syndrome and polycystic ovarian disease and reports no new clinical findings.

This study identified a new genotype, V281+I172N/V281L, linked to non-classical 21-hydroxylase deficiency, suggesting it should be considered in genetic panels for the condition.

This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.

This study found that GTx-024 and Danazol had similar effects to dihydrotestosterone on uterine tissue in mice, while GTx-007 showed minimal impact on the parameters tested.

This article discusses the systematic diagnostic evaluation of secondary amenorrhea and provides guidance for referral considerations; it reports no new research findings.

Hormones, especially androgens, play a key role in causing acne, and treatments like hormone control pills and hormone-blocking medications can help.

This source reports that clinical trials using advanced Deep Brain Stimulation systems, augmented with AI to integrate kinematic data, eye tracking, and cognitive assessments, show promise in improving diagnostic accuracy and monitoring symptoms for patients with Parkinson's disease.

This source provides an overview of diagnostic and treatment innovations for gastrointestinal disorders, such as wireless capsule technology for motility assessment and new methods for treating constipation and nausea, highlighting both current and emerging techniques.

This study found that in a sample of girls and adolescents aged 15–24 years, the prevalence of PCOS was 22.5% according to the Rotterdam criteria.

This review discusses current knowledge of isolated premature pubarche in infants and reports no new findings, highlighting it as a mild, self-limiting condition that necessitates exclusion of serious causes.

This paper reviews causes of hirsutism in women and emphasizes the importance of identifying underlying conditions for risk assessment, though it reports no new clinical findings.

This case report presents the first known instance of combined polycystic ovary syndrome and autoimmune polyglandular syndrome type 2 in a patient, exploring potential mechanisms for their interrelation.